Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2020 / N 1

Гиперурикемия и сердечно-сосудистый риск: современный взгляд на проблему
М.М. Руда, Ю.А. Карпов

References

1. Boytsov SA, Andreyev EM, Samorodskaya IV. Comparison of mortality rates from diseases of circulatory system in Russia and the United States. Kardiologiia 2017;57(1):5-16 (In Russian).
2. World Health Organization. Fact sheets/detail. Cardiovascular diseases (CVDs). 2017 May 17. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) Accessed 2020 Aug 10. (In Russian).
3. Saygitov RT, Chulok AA. Cardiovascular diseases in the context of Russia’s long-term socio-economic development priorities. Annals of the Russian Academy of Medical Sciences 2015;70(3):286-99 (In Russian).
4. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2017 update: a report from the American Heart Association. Circulation 2017;135(10):e146-603.
5. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ 2010 Sep;341:c4986.
6. Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, Iseki K, Jassal SK, Heejin Kimm H, Kronenberg F, Oien CM, Levey AS, Levin A, Woodward M, Hemmelgarn BR; Chronic Kidney Disease Prognosis Consortium. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 2013 Jan;346:f324.
7. Lopes NH, da Silva Paulitsch F, Pereira A, Garzillo CL, Ferreira JF, Stolf N, Hueb W. Mild chronic kidney dysfunction and treatment strategies for stable coronary artery disease. The Journal of Thoracic and Cardiovascular Surgery 2009 Jun;137(6):1443-9.
8. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfou Fd, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal 2020 Jan;41(3):407-77.
9. Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, Barbarash OL, Boytsov SA, Vavilova TV, Villevalde SV, Galyavich AS, Glezer MG, Grineva EN, Grinstein YuI, Drapkina OM, Zhernakova YuV, Zvartau NE, Kislyak OA, Koziolova NA, Kosmacheva ED, Kotovskaya YuV, Libis RA, Lopatin YuM, Nebiyeridze DV, Nedoshivin AO, Ostroumova OD, Oshchepkova EV, Ratova LG, Skibitskiy VV, Tkacheva ON, Chazova IE, Chesnikova AI, Chumakova GA, Shalnova SA, Shestakova MV, Yakushin SS, Yanishevskiy SN. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology 2020;25(3):149-218 (In Russian).
10. Roddy E, Doherty M. Epidemiology of gout. Arthritis Research & Therapy 2010;12(6):22-34.
11. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. The American Journal of Medicine 2012 Jul;125(7):679-87.e1.
12. Mumford SL, Dasharathy SS, Pollack AZ, Perkins NJ, Mattison DR, Cole SR, Wactawski-Wende J, Schisterman EF. Serum uric acid in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study. Human Reproduction 2013 Jul;28(7):1853-62.
13. Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women. The Third National Health and Nutrition Examination Survey. Arthritis Research & Therapy 2008;10(5):1-7.
14. Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. The Lancet 1999 Aug;354(9179):650.
15. Nasonova VA, Barskova VG. Early diagnosis and treatment of gout is a scientifically substantiated requirement to improve the labor and life prognosis of patients. Rheumatology Science and Practice 2004;42(1):5-7(In Russian).
16. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nature Reviews. Rheumatology 2015 Nov;11(11):649-62.
17. Choi H, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007 Aug;116(8):894-900.
18. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH; MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Archives of Internal Medicine 2008 May;168(10):1104-10.
19. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension (Dallas, Tex.: 1979) 2001 Nov;38(5):1101-6.
20. Dehghan A, van Hoek M, Sijbrands EJG, Hofman A, Witteman JCM. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008 Feb;31(2):361-2.
21. Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 2005 Jan;45(1):34-8.
22. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. Journal of the American Society of Nephrology 2002 Dec;13(12):2888-97.
23. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal 2018 Sep;39(33):3021-04.
24. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care & Research (Hoboken) 2011 Jan;63:102-10.
25. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? British Journal of Clinical Pharmacology 2006 Dec;62(6):633-44.
26. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension (Dallas, Tex.: 1979) 2005 Dec;45(1):18-20.
27. Forman JP, Choi H, Curhan GC. Uric acid and insulin sensitivity and risk of incident hypertension. Archives of Internal Medicine 2009 Jan;169(2):155-62.
28. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria JC, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz PF, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases 2017 Jan;76(1):29-42.
29. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, Manolis AJ, Perez-Ruiz F, Mancia G. Serum uric acid and the risk of cardiovascular and renal disease. Journal of Hypertension 2015 Sep;33(9):1729-41; discussion 1741.
30. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis & Rheumatology 2004 Jun;51(3):321-5.
31. Yü TF, Berger L, Dorph DJ, Smith H. Renal function in gout. V. Factors influencing the renal hemodynamics. The American Journal Medicine 1979 Nov;67(5):766-71.
32. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991;59(3):364-8.
33. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Annals of Internal Medicine 1980 Dec;93(6):817-21.
34. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension (Dallas, Tex.: 1979) 2003 Sep;42(3):247-52.
35. Lee JE, Kim YG, Choi YH, Huh W, Kim DJ, Oh HY. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension (Dallas, Tex.: 1979) 2006 May;47(5):962-7.
36. Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. Journal of Hypertension 2007 Aug;25(8):1583-9.
37. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension (Dallas, Tex.: 1979) 2007 Feb;49(2):298-303.
38. Mellen P, Bleyer A, Erlinger T, Evans GW, Nieto FJ, Wagenknecht LE, Wofford MR, Herrington DM. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension (Dallas, Tex.: 1979) 2006 Dec;48(6):1037-42.
39. Bombelli M, Ronchi I, Volpe M, Facchetti R, Carugo S, Dell’oro R, Cuspidi C, Grassi G, Mancia G. Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality. Journal of Hypertension 2014 Jun;32(6):1237-44.
40. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, Weiss ST, Litonjua AA. Uric acid and the development of hypertension: the normative aging study. Hypertension (Dallas, Tex.: 1979) 2006 Dec;48(6):1031-6.
41. Zhang W, Sun K, Yang Y, Zhang H, Hu FB, Hui R. Plasma uric acid and hypertension in a Chinese community: prospective study and meta-analysis. Clinical Chemistry 2009 Nov;55(11):2026-34.
42. Shankar A, Klein R, Klein BEK, Nieto FJ. The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. Journal of Human Hypertension 2006 Dec;20(12):937-45.
43. Sundström J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension (Dallas, Tex.: 1979) 2005 Jan;45(1):28-33.
44. Kuwabara M, Hisatome I, Niwa K, Shigeko Hara S, Roncal-Jimenez CA, Bjornstad P, Nakagawa T, Andres-Hernando A, Sato Y, Jensen T, Garcia G, Rodriguez-Iturbe B, Ohno M, Lanaspa MA, Johnson RJ. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese Cohort Study. Hypertension (Dallas, Tex.: 1979) 2018 Jan;71(1):78-86.
45. Kuwabara M, Borghi C, Cicero AFG, Hisatome I, Niwa K, Ohno M, Johnson RJ, Lanaspa MA. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan. International Journal of Cardiology 2018 Jun;261:183-8.
46. Norvik JV, Storhaug HM, Ytrehus K, Jenssen TG, Zykova SN, Eriksen BO, Solbu MD. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: the Troms@ø Study. BMC. Cardiovascular Disorders 2016 May;16:85.
47. Mantovani A, Rigolon R, Civettini A, Bolzan B, Morani G, Bonapace S, Dugo C, Zoppini G, Bonor E, Targher G. Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24h Holter monitoring. Journal of Endocrinological Investigation 2018 Feb;41(2):223-31.
48. Kuwabara M, Niwa K, Nishihara S, Nishi Y, Takahashi O, Kario K, Yamamoto K, Yamashita T, Hisatome I. Hyperuricemia is an independent competing risk factor for atrial fibrillation. International Journal of Cardiology 2017 Mar;231:137-42.
49. Krishnan E, Pandya BJ, Lingala B, Hariri A, Dabbous O. Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. Arthritis Research & Therapy 2012 Jan;14(1):R10.
50. Bos MJ, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MMB. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006 Jun;37(6):1503-7.
51. Tscharre M, Herman R, Rohla M, Hauser C, Farhan S, Freynhofer M, Huber K, Weiss TW. Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Atherosclerosis 2018 Mar;270:173-9.
52. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Journal of Internal Medicine 2009 Dec;266(6):558-70.
53. Crosta F, Occhiuzzi U, Passalacqua G, Occhiuzzi E, Cimini A, Grassi D, Ferri C, Marini C, Borghi C, Desideri G. Association between the serum uric acid levels and lacunar infarcts in the elderly. Journal of Molecular Neuroscience 2018 Jul;65(3):385-90.
54. Stack AG, Hanley A, Casserly LF, Cronin CJ, Abdalla AA, Kiernan TJ, Murthy BVR, Hegarty A, Hannigan A, Nguyen HT. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 2013 Jul;106(7):647-58.
55. Kuo CF, See LC, Yu KH, Chou IJ, Chiou MJ, Luo SF. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford, England) 2013 Jan;52(1):127-34.
56. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Archives of Internal Medicine 2010 Aug;170(15):1358-64.
57. Eliseyev MS. Algorithm for diagnosis and treatment of gout. Russian Medical Journal 2015;23(7):410-4 (In Russian).
58. Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, So AK, Bardin T. Gout: why is this curable disease so seldom cured? Annals of the Rheumatic Diseases 2012 Nov;71(11):1765-70.
59. Eminaga F, La-Crette J, Jones A, Abhishek A. Does the initiation of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. Rheumatology International 2016 Dec;36(12):1747-52.
60. Grassi G, Bombelli M, Sega R, Trevano FQ. The PAMELA (Pressioni Arteriose Monitorate E Loro Associazioni) Study. High Blood Pressure & Cardiovascular Prevention 2007;14(2):83-8.
61. Russian Medical Society on Arterial Hypertension. Guidelines on treatment of patients with arterial hypertension with metabolic disorders and diabetes mellitus type 2. Systemic Hypertension 2020;17(1):7-45 (In Russian).
62. Choi HK, Soriano LC, Zhang Y, Rodríguez LAG. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case–control study. BMJ 2012 Jan;344:d8190.
63. Choi HK, Athinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Archives in Internal Medicine 2005 Apr;165(7):742-8.
64. Fotherby MD, Potter JF. Metabolic and orthostatic blood pressure responses to a low-sodium diet in elderly hypertensives. Journal of Human Hypertension 1997 Jun;11(6):361-6.
65. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Current Opinion in Rheumatology 2011 Mar;23(2):192-202.
66. Spinar J, Vítovec J, Soucek M, Dusek L, Pavlík T; CORD Invesigators. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers. Vnitr̆ní lékar̆ství 2009 May;55(5):481-8.
67. Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Schneider KA, Pressel S. Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Archives of Internal Medicine 1987 Apr;147(4):645-9.
68. Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annual Reviews of Physiology 2015;77(1):323-45.
69. Khanna D, Fitzgerald J, Khanna P, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Gerald Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout part 1: systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care & Research 2012 Oct;64(10):1431-46.
70. Eliseyev MS. Updated EULAR guidelines for gout management. Comments on certain items. Scientific and Practical Rheumatology 2017;55(6):600-9 (In Russian).
71. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. The New England Journal of Medicine 2018 Mar;378(13):1200-10.
72. Jansen TLTA, Janssen M. Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. Clinical Rheumatology 2019 Jan;38(1):263-5.
73. Agarwal A, Banerjee A, Banerjee UC. Xanthine oxidoreductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling. Critical Reviews in Biotechnology 2011 Sep;31(3):264-80.
74. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacological Reviews 2006 Mar;58(1):87-114.
75. Robins RK. Potential purine antagonists. I. Synthesis of some 4,6-substituted pyrazolo [3,4-d] pyrimidines. Journal of the American Chemistry Society 1956 Feb;78(4):784-90.
76. Benn CL, Dua P, Gurrell R, Loudon P, Pike A, Storer R, Vangjeli C. Physiology of hyperuricemia and urate-lowering treatments. Frontiers in Medicine (Lausanne) 2018;5:160.
77. Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM. Impact of allopurinol use on urate concentration and cardiovascular outcome. British Journal of Clinical Pharmacology 2011 Apr;71(4):600-7.
78. Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, Drake J, Dalbeth N. A randomized controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases 2017 Sep;76(9):1522-8.
79. Corbett EJM, Pentony P, McGill NW. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice. International Journal of Rheumatic Diseases 2017 Jul;20(7):894-7.
80. Eliseyev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin 1β blocker canakinumab in patients with chronic tophaceous gout: relief of arthritis and prevention of exacerbations when allopurinol is used. Modern Rheumatology 2015;9(2):16-22 (In Russian).
81. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G; British Society for Rheumatology and British Health Professionals in Rheumatology Standards Guidelines and Audit Working Group (SGAWG). British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford, England) 2007 Aug;46(8):1372-4.
82. Eliseyev MS. Gout. Moscow: Geotar-Media; 2019. 240 p. (In Russian).
83. Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, Baumgartner S. An open-label, 6-month study of allopurinol safety in gout: the LASSO study. Seminars in Arthritis and Rheumatism 2015 Oct;45(2):174-83.
84. Levy G, Shi JM, Cheetham TC, Rashid N. Urate-lowering therapy in moderate to severe chronic kidney disease. The Permanente Journal 2018;22:17-142.
85. Reinders MK, Haagsma C, Jansen T, van Roon EN, Delsing J, van de Laar MAFJ, Brouwers JRBJ. A randomized controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Annals of Rheumatic Diseases 2009 Jun;68(6):892-7.
86. Perez-Ruiz F, Castillo E, Chinchilla SP, Herrero-Beites AM. Clinical manifistations and diagnosis of gout. Rheumatic Diseases Clinics of North America 2014 May;40(2):193-206.
87. Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Pérez de Jose A, Cedeño S, Linares T, Luño J. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. American Journal of Kidney Diseases 2015 Apr;65(4):543-9.
88. MacIsaac RL, Salatzki J, Higgins P, Walters MR, Padmanabhan S, Dominiczak AF, Touyz RM, Dawson J. Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension (Dallas, Tex.: 1979) 2016 Mar;67(3):535-40.
89. Stamp L, Merriman T, Barclay M, Singh JA, Roberts RL, Wright DF, Dalbeth N. Impaired response or insufficient dosage? Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout. Seminars in Arthritis and Rheumatism 2014 Oct;44(2):170-4.
90. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. Journal of Clinical Rheumatology 2006 Apr;12(2):61-5.
91. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. The Journal of Rheumatology 2004 Dec;31(12):2429-32.
92. Zhelyabina OV, Chikina MN, Eliseyev MS. Allopurinol for treating gout. Doctor.ru 2017;10(139):57-62 (In Russian).
93. Beattie CJ, Fulton RL, Higgins P, Padmanabhan S, McCallum L, Walters MR, Dominiczak AF, Touyz RM, Dawson J. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension (Dallas, Tex.: 1979) 2014 Nov;64(5):1102-7.
94. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. The Journal of Clinical Hypertension (Greenwich, Conn.) 2013 Jun;15(6):435-42.
95. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrology 2015 Apr;16:58.
96. Kostka-Jeziorny K, Uruski P, Tykarski A. Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. Blood Pressure 2011 Apr;20(2):104-10.
97. Khan F, George J, Wong K, McSwiggan S, Struthers AD, Belch JJF. Allopurinol treatment reduces arterial wave reflection in stroke survivors. Cardiovascular Therapeutics 2008 Winter;26(4):247-52.
98. Borghi C, Desideri G. Urate-lowering drugs and prevention of cardiovascular disease: the emerging role of xanthine oxidase inhibition. Hypertension (Dallas, Tex.: 1979) 2016 Mar;67(3):496-8.
99. Ueno S, Hamada T, Taniguchi S, Ohtani N, Miyazaki S, Mizuta E, Ohtahara A, Ogino K, Yoshida A, Kuwabara M, Yoshida K, Ninomiya H, Kotake H, Taufiq F, Yamamoto K, Hisatome I. Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension: cross-sectional cohort study. Drug Research (Stuttgard) 2016 Dec;66(12):628-32.
100. Kai H, Ueda T, Uchiwa H, Iwamoto Y, Aoki Y, Anegawa T, Fukuda K, Fukumoto Y, Imaizumi T; MAPPY Study Investigators. Benefit of losartan/hydrochlorothiazide-fixed dose combination treatment for isolated morning hypertension: the MAPPY study. Clinical and Experimental Hypertension (New York, N.Y.: 1993) 2015;37(6):473-81.
101. Matsumura K, Arima H, Tominaga M, Ohtsubo T, Sasaguri T, Fujii K, Fukuhara M, Uezono K, Morinaga Y, Ohta Y, Otonari T, Kawasaki J, Kato I, Tsuchihashi T; COMFORT Investigators. Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study. Clinical and Experimental Hypertension 2015;37(3):192-6.
102. Okamura K, Shirai K, Totake N, Okuda T, Urata H. Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine. Clinical and Experimental Hypertension (New York, N.Y.: 1993) 2018;40(2):99-106.
103. Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacological Research 2015 Dec;102:63-70.
104. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. The American Heart Journal 2004 Oct;148(4):635-4.
105. Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, Tamai I. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharmaceutics & Drug Disposition 2014 Oct;35(7):391-404.
106. Kuo CF, Luo SF. Gout: risk of premature death in gout unchanged for years. Nature. Reviews Rheumatology 2017 Apr;13(4):200-1.
107. Goicoechea M, de Vinuesa SG, Verdalles U, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clinical Journal of the American Society of Nephrology 2010 Aug;5(8):1388-93.
108. Su X, Xu B, Yan B, Qiao X, Wang L. Effects of uric acid-lowering therapy in patients with chronic kidney disease: a meta-analysis. PloS One 2017 Nov;12(11):e0187550.
109. Sampson AL, Singer RF, Walters GD. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database of Systematic Reviews 2017 Oct;10(10):CD009460.
110. Levy GD, Rashid N, Niu F, Cheethem TC. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. The Journal of Rheumatology 2014 May;41(5):955-62.
111. Instructions for medical use of Milurit drug, reg. No.: P N012684/01 from 2010 Aug 31; re-registrated: 2019 Nov 06 (In Russian).
112. Noman A, Ang DSC, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomized, placebo controlled crossover trial. The Lancet 2010 Jun;375(9732):2161-7.
113. Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG, Lang CC, George J, Struthers AD. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. Journal of the American College of Cardiology 2013 Mar;61(9):926-32.
114. Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovascular Therapy 2012 Aug;30(4):217-26.
115. George J, Carr E, Davies J, Belch JJF, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006 Dec;114(23):2508-16.
116. Borghi C, Omboni S, Reggiardo G, Bacchelli S, Esposti DD, Ambrosioni E; SMILE Working Project. Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies. BMC. Cardiovascular Disorder 2018 Jun;18(1):112.
117. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O’Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran M, McNulty SE, Lee KL, Shah MR, Hernandez AF; NHLBI Heart Failure Clinical Research Network. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients. The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation 2015 May;131(20):1763-71.
118. Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T. Improving cardiovascular and renal outcomes in gout: what should we target? Nature Reviews Rheumatology 2014;10(11):654-61.
119. Okafor ON, Farrington K, Gorog DA. Allopurinol as a therapeutic option in cardiovascular disease. Pharmacology & Therapeutics 2017 Apr;172:139-50.
120. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. The New England Journal of Medicine 2008 Oct;359(17):1811-21.
121. Perez-Ruiz F, Martínez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Annals of the Rheumatic Diseases 2014 Jan;73(1):177-182.
122. Dubreuil M, Zhu Y, Seeger JD, Lu N, Rho YH, Choi HK. Allopurinol initiation and all-cause mortality in the general population. Annals of the Rheumatic Diseases 2015 Jul;74(7):1368-72.
123. Struthers A, Shearer F. Allopurinol: novel indications in cardiovascular disease. Heart 2012 Nov;98(21):1543-5.
124. Order of the Government of the Russian Federation of 12.10.2019 No 2406-R (ed. from 26.04.2020) “On approval of the list of essential and essential medicines for 2020 as well as lists of medicines for medical use and the minimum range of medicines required for medical care” (In Russian).
125. Puig JG, Martínez MA. Hyperuricemia, gout and the metabolic syndrome. Current Opinion in Rheumatology 2008 Mar;20(2):187-91.
126. Yu KH, Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, Chiou MJ. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Research & Therapy 2012 Apr;14(2):R83.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]